Abstract
Objectives To assess clinical experience with NuvaRing® in daily practice in Switzerland, including a large subgroup of young women (aged ≤22 years).
Methods Open, prospective, multicentre, observational clinical experience study to investigate cycle control, acceptability and usage of NuvaRing®.
Results Altogether, 2642 women participated in the programme and were included in the analysis, of which 658 were aged ≤22 years (25% of the total group). A total of 744 women (28% of the total group) discontinued NuvaRing® use; the main reason was adverse events (11% of all users). In younger women, there was a shift from moderate (−18%) and heavy (−45%) bleeding to mild bleeding (+71%) and dysmenorrhoea decreased by 60%, despite previous hormonal contraception use by 83% of women. Most women found ring insertion and removal to be straightforward (>95%), and were satisfied with its use (85%), primarily for the ring's once-a-month application (81%). Data were very similar for the total group. Cycle control and satisfaction were further improved with duration of treatment.
Conclusions In daily practice, NuvaRing® improved cycle control and was highly acceptable to women, including young women. Switchers from other hormonal methods also showed improved cycle control and high satisfaction.